Efficacy of montelukast and loratadine as treatment for allergic rhinitis in children

Asian Pacific Journal of Allergy and Immunology

Volumn 26, Issue 2-3, 2008, Pages 89-95

  Watanasomsiri, Apassorn ^a   Poachanukoon, Orapan ^a   Vichyanond, Pakit ^b  

^a THAMMASAT UNIVERSITY   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

LORATADINE; MONTELUKAST; PLACEBO;

ADOLESCENT; ALLERGIC RHINITIS; ARTICLE; BEDTIME DOSAGE; CHILD; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NOSE CONGESTION; NOSE SECRETION; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SINGLE BLIND PROCEDURE; UNSPECIFIED SIDE EFFECT;

ACETATES; ADOLESCENT; ASTHMA; CHILD; DRUG THERAPY, COMBINATION; FEMALE; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; LEUKOTRIENE ANTAGONISTS; LORATADINE; MALE; NASAL MUCOSA; NASAL OBSTRUCTION; QUINOLINES; RHINITIS, ALLERGIC, PERENNIAL; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 58149467905     PISSN: 0125877X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001; 108: S147-334.
2. Bisgaard H. Leukotriene modifiers in pediatric asthma management. Pediatrics 2001; 107: 381-90.
3. Miadonna A, Tedeschi A, Leggieri E, Lorini M, Folco G, Sala A, et al. Behavior and clinical relevance of histamine and leukotrienes C4 and B4 in grass pollen-induced rhinitis. Am Rev Respir Dis 1987; 136: 357-62.
4. Okuda M, Watase T, Mezawa A, Liu CM. The role of leukotriene D4 in allergic rhinitis. Ann Allergy 1988; 60: 537-40.
5. Bisgaard H, Olsson P, Bende M. Effect of leukotriene D4 on nasal mucosal blood flow, nasal airway resistance and nasal secretion in humans. Clin Allergy 1986; 16: 289-97.
6. Philip G, Malmstrom K, LaForce CF, et al. Montelukast in the treatment of nighttime symptoms associated with spring allergic rhinitis in a double-blind, randomized, placebo-controlled study. J Allergy Clin Immunol 2001; 107: S157.
7. Malmstrom K, Hampel FC, Philip G, et al. Montelukast in the treatment of spring allergic rhinitis in a large, double-blind, randomized, placebo-controlled study. J Allergy Clin Immunol 2001; 107: S157.
8. Meltzer EO, Malmstrom K, Lu S, Prenner BM, Wei LX, Weinstein SF, et al. Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: a randomized, placebo-controlled clinical trial. J Allergy Clin Immunol 2000; 105: 917-22.
9. Michele TM, Lu S, Malice MP, et al. The Montelukast Allergic Rhinitis Study Group. Combination of montelukast and loratadine in seasonal allergic rhinitis: an analysis of three spring studies. J Allergy Clin Immunol 2000; 105: S387.
10. Coelho M, Saconato H, Castelo A. Topical nasal steroids for allergic rhinitis in children. The Cochrane Database of Systematic Reviews 2003; 3.
11. Skoner DP, Rachelefsky GS, Meltzer EO, Chervinsky P, Morris RM, Seltzer JM, et al. Detection of growth suppression in children during treatment with intranasal beclomethasone dipropionate. Pediatrics 2000; 105: E23.
12. Knorr B, Holland S, Rogers JD, Nguyen HH, Reiss TF. Montelukast adult (10-mg film-coated tablet) and pediatric (5-mg chewable tablet) dose selections. J Allergy Clin Immunol 2000; 106: S171-8.
13. Lipworth BJ. Leukotriene-receptor antagonists. Lancet 1999; 353: 57-62.
14. Donnelly AL, Glass M, Minkwitz MC, Casale TB. The leukotriene D4-receptor antagonist, ICI 204,219, relieves symptoms of acute seasonal allergic rhinitis. Am J Respir Crit Care Med 1995; 151: 1734-9.
15. Philip G, Malmstrom K, Hampel FC, Weinstein SF, LaForce CF, Ratner PH, et al. Montelukast for treating seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial performed in the spring. Clin Exp Allergy 2002; 32: 1020-8.
16. van Adelsberg J, Philip G, LaForce CF, Weinstein SF, Menten J, Malice MP, et al. Randomized controlled trial evaluating the clinical benefit of montelukast for treating spring seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2003; 90: 214-22.
17. Pullerits T, Praks L, Ristioja V, Lotvall J. Comparison of a nasal glucocorticoid, antileukotriene, and a combination of antileukotriene and antihistamine in the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol 2002; 109: 949-55.
18. Meltzer EO. Role for cysteinyl leukotriene receptor antagonist therapy in asthma and their potential role in allergic rhinitis based on the concept of "one linked airway disease". Ann Allergy Asthma Immunol 2000; 84: 176-85; quiz 185-7.
19. Nathan RA. Pharmacotherapy for allergic rhinitis: a critical review of leukotriene receptor antagonists compared with other treatments. Ann Allergy Asthma Immunol 2003; 90: 182-90; quiz 190-1, 232.
20. Volovitz B, Tabachnik E, Nussinovitch M, Shtaif B, Blau H, Gil-Ad I, et al. Montelukast, a leukotriene receptor antagonist, reduces the concentration of leukotrienes in the respiratory tract of children with persistent asthma. J Allergy Clin Immunol 1999; 104: 1162-7.
21. Nayak AS, Philip G, Lu S, Malice MP, Reiss TF. Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial performed in the fall. Ann Allergy Asthma Immunol 2002; 88: 592-600.
22. Gonzalez MA, Estes KS. Pharmacokinetic overview of oral second-generation H1 antihistamines. Int J Clin Pharmacol Ther 1998; 36: 292-300.
23. Corren J. Allergic rhinitis and asthma: how important is the link? J Allergy Clin Immunol 1997; 99: S781-6.
24. Braunstahl GJ, Overbeek SE, Kleinjan A, Prins JB, Hoogsteden HC, Fokkens WJ. Nasal allergen provocation induces adhesion molecule expression and tissue eosinophilia in upper and lower airways. J Allergy Clin Immunol 2001; 107: 469-76.
25. Boulay ME, Boulet LP. Lower airway inflammatory responses to repeated very-low-dose allergen challenge in allergic rhinitis and asthma. Clin Exp Allergy 2002; 32: 1441-7.
26. Beeh KM, Beier J, Kornmann O, Meier C, Taeumer T, Buhl R. A single nasal allergen challenge increases induced sputum inflammatory markers in non-asthmatic subjects with seasonal allergic rhinitis: correlation with plasma interleukin-5. Clin Exp Allergy 2003; 33: 475-82.
27. Braunstahl GJ, Kleinjan A, Overbeek SE, Prins JB, Hoogsteden HC, Fokkens WJ. Segmental bronchial provocation induces nasal inflammation in allergic rhinitis patients. Am J Respir Crit Care Med 2000; 161: 2051-7.
28. Corren J, Adinoff AD, Irvin CG. Changes in bronchial responsiveness following nasal provocation with allergen. J Allergy Clin Immunol 1992; 89: 611-8.
29. Bentley AM, Jacobson MR, Cumberworth V, Barkans JR, Moqbel R, Schwartz LB, et al. Immunohistology of the nasal mucosa in seasonal allergic rhinitis: increases in activated eosinophils and epithelial mast cells. J Allergy Clin Immunol 1992; 89: 877-83.
30. Bradding P, Roberts JA, Britten KM, Montefort S, Djukanovic R, Mueller R, et al. Interleukin-4, -5, and -6 and tumor necrosis factor-alpha in normal and asthmatic airways: evidence for the human mast cell as a source of these cytokines. Am J Respir Cell Mol Biol 1994; 10: 471-80.
31. Bradding P, Feather IH, Wilson S, Bardin PG, Heusser CH, Holgate ST, et al. Immunolocalization of cytokines in the nasal mucosa of normal and perennial rhinitic subjects. The mast cell as a source of IL-4, IL-5, and IL-6 in human allergic mucosal inflammation. J Immunol 1993; 151: 3853-65.
32. Pullerits T, Praks L, Skoogh BE, Ani R, Lotvall J. Randomized placebo-controlled study comparing a leukotriene receptor antagonist and a nasal glucocorticoid in seasonal allergic rhinitis. Am J Respir Crit Care Med 1999; 159: 1814-8.
33. Saengpanich S, deTineo M, Naclerio RM, Baroody FM. Fluticasone nasal spray and the combination of loratadine and montelukast in seasonal allergic rhinitis. Arch Otolaryngol Head Neck Surg 2003; 129: 557-62.
34. Storms W, Michele TM, Knorr B, Noonan G, Shapiro G, Zhang J, et al. Clinical safety and tolerability of montelukast, a leukotriene receptor antagonist, in controlled clinical trials in patients aged > or = 6 years. Clin Exp Allergy 2001; 31: 77-87.
35. Reiss TF, Chervinsky P, Dockhorn RJ, Shingo S, Seidenberg B, Edwards TB. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group. Arch Intern Med 1998; 158: 1213-20.
36. Knorr B, Matz J, Bernstein JA, Nguyen H, Seidenberg BC, Reiss TF, et al. Montelukast for chronic asthma in 6- to 14-year-old children: a randomized, double-blind trial. Pediatric Montelukast Study Group. Jama 1998; 279: 1181-6.
37. Knorr B, Franchi LM, Bisgaard H, Vermeulen JH, LeSouef P, Santanello N, et al. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics 2001; 108: E48.
38. Holgate S. What is the place of leukotriene receptor antagonist in clinical practice? Eur Respir Rev 2001; 11: 41-6.